Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers.
Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Hamada K, Suzuki H. Muto S, et al. Among authors: yamaura t. Biomedicines. 2023 Jan 12;11(1):190. doi: 10.3390/biomedicines11010190. Biomedicines. 2023. PMID: 36672698 Free PMC article. Review.
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
Ozaki Y, Muto S, Takagi H, Watanabe M, Inoue T, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, Ohsugi J, Hoshino M, Shio Y, Tanaka D, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Ozaki Y, et al. Among authors: yamaura t. Cancer Immunol Immunother. 2020 Jan;69(1):127-134. doi: 10.1007/s00262-019-02446-1. Epub 2019 Dec 6. Cancer Immunol Immunother. 2020. PMID: 31807880 Free PMC article.
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden.
Muto S, Ozaki Y, Yamaguchi H, Mine H, Takagi H, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Muto S, et al. Among authors: yamaura t. Oncol Lett. 2021 Mar;21(3):203. doi: 10.3892/ol.2021.12464. Epub 2021 Jan 12. Oncol Lett. 2021. PMID: 33574942 Free PMC article.
Recent advances in immunotherapy for non-small-cell lung cancer.
Suzuki H, Owada Y, Watanabe Y, Inoue T, Fukuharav M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Ohsugi J, Hoshino M, Higuchi M, Shio Y, Gotoh M. Suzuki H, et al. Among authors: yamaura t. Hum Vaccin Immunother. 2014;10(2):352-7. doi: 10.4161/hv.26919. Epub 2013 Nov 6. Hum Vaccin Immunother. 2014. PMID: 24196313 Free PMC article. Review.
Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma.
Osugi J, Kimura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Hoshino M, Higuchi M, Shio Y, Suzuki H, Gotoh M. Osugi J, et al. Among authors: yamaura t. J Oncol. 2015;2015:316745. doi: 10.1155/2015/316745. Epub 2015 Feb 5. J Oncol. 2015. PMID: 25733977 Free PMC article.
160 results